Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302462 | 0.93 | LMNA (0.70) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL5661423 | 0.91 | LMNA (0.64) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL5314942 | 0.89 | LTA4H (0.73) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL5659325 | 0.86 | LMNA (0.70) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL5313298 | 0.84 | ALDH1A1 (0.58) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL1181487 | 0.83 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL5660490 | 0.83 | ALDH1A1 (0.73) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL28604386 | 0.83 | KCNA5 (0.60) | SMN1; SMN2ALDH1A1KCNA5MEN1KMT2A | |
| SCHEMBL3301598 | 0.82 | ALDH1A1 (0.59) | LMNASMN1; SMN2GAAALDH1A1MAPT | |
| SCHEMBL1181333 | 0.82 | ALDH1A1 (0.59) | LMNASMN1; SMN2GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-04-22 | — | — | US | claimed |
| EP-2099752-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2009-09-16 | — | — | EP | claimed |
| WO-2008052769-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | WO | claimed |
| EP-1918281-A1 | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-04-22 | — | — | US | disclosed |
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-04-22 | — | — | US | disclosed |
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2010-04-22 | — | — | US | disclosed |
| EP-2099752-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008052769-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008052769-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918281-A1 | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099703-A1 | PHENYLAMINO-SUBSTITUTED PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PIGO, PNMT, CAT | LMNA 475/4885SMN1; SMN2 2771/4885GAA 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.